Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8894586 | 0.82 | FUCA1 (0.51) | GAASIGMAR1CYP2D6MEN1KMT2A | |
| SCHEMBL8892761 | 0.82 | CYP2D6 (0.51) | GAASIGMAR1CYP2D6MEN1KMT2A | |
| SCHEMBL23727894 | 0.76 | SIGMAR1 (0.54) | GAASIGMAR1CYP2D6MEN1KMT2A | |
| SCHEMBL3464617 | 0.76 | CYP2D6 (0.61) | GAASIGMAR1CYP2D6MEN1KMT2A | |
| SCHEMBL31230946 | 0.76 | CYP2D6 (0.61) | GAASIGMAR1CYP2D6MEN1KMT2A | |
| SCHEMBL15985246 | 0.74 | CYP2D6 (0.60) | GAASIGMAR1CYP2D6MEN1KMT2A | |
| SCHEMBL31230966 | 0.74 | CYP2D6 (0.59) | GAASIGMAR1CYP2D6MEN1KMT2A | |
| SCHEMBL14089988 | 0.74 | MC4R (0.58) | GAASIGMAR1CYP2D6MEN1KMT2A | |
| SCHEMBL17706684 | 0.74 | SIGMAR1 (0.52) | GAASIGMAR1CYP2D6MEN1KMT2A | |
| SCHEMBL14892774 | 0.73 | DRD4 (0.59) | GAASIGMAR1CYP2D6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | CHRM4, CHRM2, CHRM5 | GAA 2002/4885SIGMAR1 343/4885CYP2D6 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.